Full Press Release Details
Leadership and Investigators to Present at Five Scientific Events in May
N.C. - May 6, 2021 - Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable
bioengineered human tissue at commercial scale, today announced that clinical investigators and senior leadership will present at five
scientific and medical events in May 2021.
look forward to showcasing Humacyte's leadership in tissue engineering among our peers and with the next crop of surgical leaders
at distinguished scientific meetings and events," said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. "I'm
also particularly excited to present - for the first time - updates on progress in our early development program in lung
tissue engineering at the Annual Meeting of the Japanese Association for Chest Surgery."
details of the events are as follows:
Symposium on Biologic Scaffolds for Regenerative Medicine
Engineered Matrix in the Vascular System - Remodeling and Function
presentation will summarize Humacyte's ongoing human acellular vessel (HAV) development program in vascular repair, reconstruction
/ time: Thursday, May 6, 2021, 5:30-6:30 p.m. PDT
Laura Niklason, M.D., Ph.D., Chief Executive Officer, Humacyte
David C. Sabiston Jr. Distinguished Surgical Lecture
Bioengineered Human Acellular Vessels for Use in Vascular Injury - Repair, Replacement and Reconstruction
grand rounds lecture will highlight the HAV's potential to address civilian and military vascular trauma injuries.
The Department of Surgery at Uniformed Services University of the Health Sciences & the Walter Reed National Military Medical Center
/ time: Wednesday, May 19, 2021, 9-10 a.m. EDT
Jeffrey Lawson, M.D., Ph.D., Chief Surgical Officer, Humacyte
Association of Pharmaceutical Scientists National Biotechnology Conference
Vascular Tissue Engineering
presentation will cover the unmet needs in vascular repair and reconstruction, and the HAV platform technology, manufacturing processes
and current clinical data.
/ time: Wednesday, May 19, 2021, 2-3 p.m. EDT
Bill Tente, Chief Regulatory Officer, Humacyte
Annual Meeting of the Japanese Association for Chest Surgery
International Session 2
Recent Progress in Whole Lung Engineering
presentation will detail laboratory and pre-clinical models of whole lung engineering which demonstrate progress in the growth of functional
/ time: Friday, May 21, 2021
Laura Niklason, M.D., Ph.D., Chief Executive Officer, Humacyte
Access Society of the Americas 2021 Spring Virtual Conference
Recent Developments in Hemodialysis Access Creation and Management
Bioengineered Human Acellular Vessels: Similarities and Differences from Traditional Access Conduits
presentation will provide an overview of how Humacyte's HAV functions in clinical practice.
/ time: Saturday, May 22, 2021, 2:35-3:50 p.m. EDT
C. Keith Ozaki, M.D., the John A. Mannick Professor of Surgery, Brigham and Women's Hospital/Harvard Medical School and the Vice-Chair,
Department of Surgery at the Brigham, and principal investigator of Humacyte's HAV Phase 3 trials in vascular access
February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) ("AHAC"), a special purpose acquisition company, and
Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing
Acellular Vessels (HAV) are engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction
and replacement. HAV is intended to overcome long-standing limitations in vessel tissue repair and replacement - it can be manufactured
at commercial scale, it eliminates the need for harvesting a vessel from a patient, and clinical evidence suggests that it is non-immunogenic,
infection-resistant, and can become durable living tissue. HAV is currently being evaluated in two Phase 3 trials in AV access and a
Phase 2/3 trial for vascular trauma, and has been used in more than 430 patient implantations. It is the first product to receive Regenerative
Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration, and has also received FDA Fast Track designation.
Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed
to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat
a wide range of diseases, injuries and chronic conditions. Humacyte's initial opportunity, a portfolio of human acellular vessels
(HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous
access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts,
pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's HAVs were the
first product to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority
designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Alpha Healthcare Acquisition Corp.
Alpha Healthcare Acquisition Corp. (ticker: AHAC) is a special purpose acquisition company formed for the purpose of effecting a
business combination with one or more businesses in the healthcare sector ("AHAC"). The company was founded by Mr. Rajiv
Shukla who has two decades of buyouts, investments and operations experience in the healthcare industry. Mr. Shukla previously served
as Chairman and Chief Executive Officer of Constellation Alpha Capital Corp., a Nasdaq-listed special purpose acquisition company,
that merged with DermTech, Inc (ticker: DMTK) in August 2019. On February 17, 2021, AHAC announced a definitive agreement to merge
with Humacyte, Inc. along with a concurrent fully committed PIPE placement of $175 million of AHAC common shares at a price of $10.00
Information About the Merger and Where to Find It
A full description of the terms of the business combination will be provided in a registration statement on Form S-4 filed with the
SEC by AHAC that includes a prospectus with respect to the Combined Company's securities to be issued in connection with the business
combination and a proxy statement with respect to the shareholder meeting of AHAC to vote on the business combination. AHAC urges its
investors, shareholders and other interested persons to read, the preliminary proxy statement/ prospectus as well as other documents
filed with the SEC because these documents will contain important information about AHAC, Humacyte and the business combination. After
the registration statement is declared effective, the definitive proxy statement/prospectus included in the registration statement will
be mailed to shareholders of AHAC as of a record date to be established for voting on the proposed business combination. Shareholders
will also be able to obtain a copy of the Form S-4, including the proxy statement/prospectus, and other documents filed with the SEC
without charge, by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas, 5th Floor,
New York, New York 10036. The preliminary and definitive proxy statement/prospectus to be included in the registration statement,
can also be obtained, without charge, at the SEC's website (www.sec.gov).
AHAC and Humacyte and their respective directors and executive officers may be considered participants in the solicitation of proxies
with respect to the proposed business combination described in this press release under the rules of the SEC. Information about the directors
and executive officers of AHAC is set forth in AHAC's final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities
Act of 1933, as amended (the "Securities Act") on September 17, 2020, and is available free of charge at the SEC's
website at www.sec.gov or by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas,
5th Floor, New York, New York 10036. Information regarding the persons who may, under the rules of the SEC,
be deemed participants in the solicitation of the AHAC shareholders in connection with the proposed business combination will be set
forth in the registration statement containing the proxy statement/prospectus for the proposed business combination. These documents
can be obtained free of charge from the sources indicated above.
This press release contains forward-looking statements that are based on beliefs and assumptions and on information
currently available. In some cases, you can identify forward-looking statements by the following words: "may," "will,"
"could," "would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential," "continue,"
"ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain
these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance
or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we
believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these
statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot
be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the initiation, timing,
progress and results of our clinical trials; the anticipated characteristics and performance of our HAVs, our ability to successfully
complete, clinical trials for our HAVs; the anticipated benefits of our HAVs relative to existing alternatives; the commercialization
of our HAVs and our ability to manufacture at commercial scale; the implementation of our business model, strategic plans for our business;
the scope of protection we are able to establish and maintain for intellectual property rights covering our HAVs and related technology;
the timing or likelihood of regulatory filings and approvals; timing, scope and rate of reimbursement for our HAVs; our estimated available
market opportunity; the proposed business combination, including the timing and structure of the business combination, the proceeds of
the business combination, and the benefits of the business combination. We cannot assure you that the forward-looking statements in this